Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 9 | 2025 | 506 | 2.080 |
Why?
|
| Chronic Pain | 2 | 2025 | 154 | 0.970 |
Why?
|
| Acute Pain | 1 | 2025 | 21 | 0.930 |
Why?
|
| Analgesics, Opioid | 3 | 2025 | 536 | 0.930 |
Why?
|
| Nicotine | 1 | 2025 | 117 | 0.860 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2025 | 71 | 0.850 |
Why?
|
| Drug Overdose | 3 | 2025 | 131 | 0.830 |
Why?
|
| Delay Discounting | 1 | 2020 | 3 | 0.700 |
Why?
|
| Intimate Partner Violence | 2 | 2017 | 25 | 0.660 |
Why?
|
| Smoking Cessation | 1 | 2025 | 550 | 0.630 |
Why?
|
| Veterans | 6 | 2025 | 764 | 0.580 |
Why?
|
| Anxiety | 3 | 2017 | 424 | 0.580 |
Why?
|
| Motivation | 1 | 2020 | 285 | 0.570 |
Why?
|
| Crime Victims | 2 | 2017 | 35 | 0.570 |
Why?
|
| Sex Offenses | 2 | 2017 | 47 | 0.560 |
Why?
|
| Self-Control | 1 | 2017 | 9 | 0.560 |
Why?
|
| Stalking | 1 | 2017 | 2 | 0.560 |
Why?
|
| Opiate Substitution Treatment | 4 | 2025 | 205 | 0.530 |
Why?
|
| Depressive Disorder, Major | 7 | 2012 | 255 | 0.510 |
Why?
|
| Adaptation, Psychological | 2 | 2017 | 265 | 0.500 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 192 | 0.480 |
Why?
|
| Emotions | 1 | 2017 | 223 | 0.460 |
Why?
|
| Harm Reduction | 2 | 2025 | 33 | 0.460 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2020 | 397 | 0.340 |
Why?
|
| Antidepressive Agents | 5 | 2011 | 225 | 0.330 |
Why?
|
| Alcoholism | 2 | 2025 | 318 | 0.320 |
Why?
|
| Patient Discharge | 2 | 2022 | 511 | 0.280 |
Why?
|
| Humans | 27 | 2025 | 63298 | 0.280 |
Why?
|
| Substance-Related Disorders | 2 | 2025 | 732 | 0.280 |
Why?
|
| Students | 2 | 2017 | 217 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 735 | 0.220 |
Why?
|
| Pharmacists | 1 | 2025 | 126 | 0.210 |
Why?
|
| Behavior Therapy | 1 | 2025 | 167 | 0.210 |
Why?
|
| Suicide | 1 | 2025 | 132 | 0.200 |
Why?
|
| Pain Management | 1 | 2025 | 161 | 0.200 |
Why?
|
| Aftercare | 1 | 2022 | 76 | 0.180 |
Why?
|
| Acupuncture Therapy | 2 | 2012 | 19 | 0.180 |
Why?
|
| Buprenorphine | 2 | 2021 | 191 | 0.180 |
Why?
|
| Residential Treatment | 1 | 2020 | 34 | 0.170 |
Why?
|
| Treatment Outcome | 8 | 2022 | 5657 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 735 | 0.170 |
Why?
|
| Quality of Life | 2 | 2025 | 1226 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 760 | 0.160 |
Why?
|
| Self Efficacy | 1 | 2020 | 201 | 0.160 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2020 | 123 | 0.150 |
Why?
|
| Violence | 2 | 2017 | 170 | 0.150 |
Why?
|
| Health Policy | 1 | 2020 | 192 | 0.150 |
Why?
|
| Adult | 10 | 2025 | 16782 | 0.150 |
Why?
|
| Rumination, Cognitive | 1 | 2017 | 1 | 0.140 |
Why?
|
| Behavioral Sciences | 1 | 2017 | 2 | 0.140 |
Why?
|
| Avoidance Learning | 1 | 2017 | 26 | 0.140 |
Why?
|
| Sex Factors | 3 | 2025 | 979 | 0.140 |
Why?
|
| Psychological Trauma | 1 | 2017 | 21 | 0.140 |
Why?
|
| Rape | 1 | 2016 | 15 | 0.130 |
Why?
|
| Social Perception | 1 | 2016 | 41 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2013 | 390 | 0.120 |
Why?
|
| Middle Aged | 7 | 2025 | 17551 | 0.120 |
Why?
|
| Sexual and Gender Minorities | 1 | 2016 | 76 | 0.120 |
Why?
|
| Male | 13 | 2025 | 29819 | 0.110 |
Why?
|
| Age Factors | 3 | 2025 | 1560 | 0.100 |
Why?
|
| Fluoxetine | 2 | 2011 | 44 | 0.100 |
Why?
|
| Female | 13 | 2025 | 32789 | 0.100 |
Why?
|
| Suicidal Ideation | 1 | 2013 | 117 | 0.090 |
Why?
|
| Hypericum | 1 | 2011 | 3 | 0.090 |
Why?
|
| Plant Preparations | 1 | 2011 | 16 | 0.090 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2025 | 543 | 0.090 |
Why?
|
| United States | 4 | 2025 | 7829 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2011 | 53 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 137 | 0.080 |
Why?
|
| Clonazepam | 1 | 2010 | 3 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 107 | 0.080 |
Why?
|
| Narcotic Antagonists | 2 | 2021 | 136 | 0.080 |
Why?
|
| Young Adult | 5 | 2025 | 4683 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2012 | 738 | 0.080 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2008 | 12 | 0.080 |
Why?
|
| Sound | 1 | 2008 | 11 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2013 | 469 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 314 | 0.070 |
Why?
|
| Speech Perception | 1 | 2008 | 79 | 0.070 |
Why?
|
| Prevalence | 2 | 2024 | 1377 | 0.070 |
Why?
|
| Animals | 1 | 2025 | 20631 | 0.070 |
Why?
|
| Depression | 1 | 2013 | 891 | 0.060 |
Why?
|
| Aging | 1 | 2011 | 746 | 0.060 |
Why?
|
| Comorbidity | 2 | 2024 | 1121 | 0.060 |
Why?
|
| Professional Role | 1 | 2025 | 43 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2025 | 32 | 0.060 |
Why?
|
| Adolescent | 3 | 2025 | 6238 | 0.050 |
Why?
|
| Cause of Death | 1 | 2025 | 221 | 0.050 |
Why?
|
| Aged | 4 | 2025 | 14392 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 695 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 834 | 0.050 |
Why?
|
| Time Factors | 4 | 2012 | 3762 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2024 | 203 | 0.050 |
Why?
|
| Demography | 2 | 2013 | 173 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2021 | 26 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2021 | 71 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2021 | 114 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 595 | 0.040 |
Why?
|
| Narcotics | 1 | 2020 | 58 | 0.040 |
Why?
|
| Naltrexone | 1 | 2021 | 89 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2011 | 498 | 0.040 |
Why?
|
| Arousal | 1 | 2020 | 42 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 642 | 0.040 |
Why?
|
| Risk Factors | 2 | 2025 | 5341 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2020 | 70 | 0.040 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2020 | 66 | 0.040 |
Why?
|
| Methadone | 1 | 2020 | 134 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2025 | 2568 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 1006 | 0.030 |
Why?
|
| Ethanol | 1 | 2021 | 322 | 0.030 |
Why?
|
| Internet | 1 | 2020 | 469 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2017 | 146 | 0.030 |
Why?
|
| Culture | 1 | 2016 | 78 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 673 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 303 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3285 | 0.030 |
Why?
|
| Psychology, Comparative | 1 | 2013 | 1 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2013 | 60 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1543 | 0.020 |
Why?
|
| Executive Function | 1 | 2013 | 65 | 0.020 |
Why?
|
| Acupuncture Points | 1 | 2012 | 5 | 0.020 |
Why?
|
| Sertraline | 1 | 2011 | 58 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 217 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 72 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 148 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 777 | 0.020 |
Why?
|
| Outpatients | 1 | 2011 | 142 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 346 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 200 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 2010 | 32 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 372 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 6631 | 0.020 |
Why?
|
| Verbal Learning | 1 | 2008 | 20 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2008 | 52 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 463 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2008 | 149 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 573 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1275 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2008 | 232 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2571 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 2074 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2460 | 0.010 |
Why?
|